Your browser doesn't support javascript.
loading
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice.
Hassan, Ahmed O; Shrihari, Swathi; Gorman, Matthew J; Ying, Baoling; Yuan, Dansu; Raju, Saravanan; Chen, Rita E; Dmitriev, Igor P; Kashentseva, Elena; Adams, Lucas J; Mann, Colin; Davis-Gardner, Meredith E; Suthar, Mehul S; Shi, Pei-Yong; Saphire, Erica Ollmann; Fremont, Daved H; Curiel, David T; Alter, Galit; Diamond, Michael S.
Afiliação
  • Hassan AO; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Shrihari S; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Gorman MJ; Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA.
  • Ying B; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Yuan D; Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA.
  • Raju S; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Chen RE; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Dmitriev IP; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Kashentseva E; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Adams LJ; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Mann C; La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Davis-Gardner ME; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Suthar MS; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Shi PY; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Departments of Microbiology and Immunology, University of Texas Medical Branch, Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX 77555, USA.
  • Saphire EO; La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Fremont DH; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Molecular Microbiology, Washington University School of
  • Curiel DT; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Alter G; Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA.
  • Diamond MS; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 6311
Cell Rep ; 36(4): 109452, 2021 07 27.
Article em En | MEDLINE | ID: mdl-34289385
SARS-CoV-2 variants that attenuate antibody neutralization could jeopardize vaccine efficacy. We recently reported the protective activity of an intranasally administered spike protein-based chimpanzee adenovirus-vectored vaccine (ChAd-SARS-CoV-2-S) in animals, which has advanced to human trials. Here, we assessed its durability, dose response, and cross-protective activity in mice. A single intranasal dose of ChAd-SARS-CoV-2-S induced durably high neutralizing and Fc effector antibody responses in serum and S-specific IgG and IgA secreting long-lived plasma cells in the bone marrow. Protection against a historical SARS-CoV-2 strain was observed across a 100-fold vaccine dose range and over a 200-day period. At 6 weeks or 9 months after vaccination, serum antibodies neutralized SARS-CoV-2 strains with B.1.351, B.1.1.28, and B.1.617.1 spike proteins and conferred almost complete protection in the upper and lower respiratory tracts after challenge with variant viruses. Thus, in mice, intranasal immunization with ChAd-SARS-CoV-2-S provides durable protection against historical and emerging SARS-CoV-2 strains.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Virais / Anticorpos Neutralizantes / Glicoproteína da Espícula de Coronavírus / SARS-CoV-2 Limite: Animals Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Virais / Anticorpos Neutralizantes / Glicoproteína da Espícula de Coronavírus / SARS-CoV-2 Limite: Animals Idioma: En Ano de publicação: 2021 Tipo de documento: Article